Oladapo O Yeku (Oladapo Yeku)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 40

Top Topics

Combination Therapy

Endometrial Cancer

Top Venues

The New England journal of medicine

Nature communications

British journal of cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Eric J Rubin, Oladapo O Yeku, Stephen Morrissey
NEJM at ESMO - Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors. The New England journal of medicine (2024)
Eric J Rubin, Oladapo O Yeku, Stephen Morrissey
NEJM at ESMO - Ponsegromab in Cancer Cachexia. The New England journal of medicine (2024)
Yumin Wang, Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu, Haibo Yang, Fengqi Zhang, Xueping Zhu, Badi Zhou, Sean Yao, Aiko Nagayama, Sanghoon Lee, Jian Ouyang, Siang-Boon Koh, Eric L Eisenhauer, Dominique Zarrella, Kate Lu, Bo R Rueda, Lee Zou, Xiaofeng A Su, Oladapo O Yeku, Leif W Ellisen, Xiao-Song Wang, Li Lan
Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair. Nature communications 15 (1) (2024)
Eric J Rubin, Oladapo O Yeku, Stephen Morrissey
NEJM at ESMO - Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. The New England journal of medicine (2024)
Eric J Rubin, Oladapo O Yeku, Stephen Morrissey
NEJM at ESMO - Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. The New England journal of medicine (2024)
Yusuke Matoba, Dominique T Zarrella, Venkatesh Pooladanda, Maryam Azimi Mohammadabadi, Eugene Kim, Shaan Kumar, Mengyao Xu, Xingping Qin, Lauren J Ray, Kyle M Devins, Raj Kumar, Artem Kononenko, Eric Eisenhauer, Irva E Veillard, Wataru Yamagami, Sarah J Hill, Kristopher A Sarosiek, Oladapo O Yeku, David R Spriggs, Bo R Rueda
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma. British journal of cancer 130 (9) (2024)
Yumin Wang, Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu, Haibo Yang, Fengqi Zhang, Xueping Zhu, Badi Zhou, Sean Yao, Aiko Nagayama, Sanghoon Lee, Jian Ouyang, Siang-Boon Koh, Eric L Eisenhauer, Dominique Zarrella, Kate Lu, Bo R Rueda, Lee Zou, Xiaofeng A Su, Oladapo O Yeku, Leif W Ellisen, Xiao-Song Wang, Li Lan
Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair. Nature communications 15 (1) (2024)
Yumin Wang, Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu, Haibo Yang, Fengqi Zhang, Xueping Zhu, Badi Zhou, Sean Yao, Aiko Nagayama, Sanghoon Lee, Jian Ouyang, Siang-Boon Koh, Eric L Eisenhauer, Dominique Zarrella, Kate Lu, Bo R Rueda, Lee Zou, Xiaofeng A Su, Oladapo O Yeku, Leif W Ellisen, Xiao-Song Wang, Li Lan
Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair. Nature communications 15 (1) (2024)
Eric J Rubin, Oladapo O Yeku, Stephen Morrissey
NEJM at ESMO - Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. The New England journal of medicine (2024)
Yusuke Matoba, Dominique T Zarrella, Venkatesh Pooladanda, Maryam Azimi Mohammadabadi, Eugene Kim, Shaan Kumar, Mengyao Xu, Xingping Qin, Lauren J Ray, Kyle M Devins, Raj Kumar, Artem Kononenko, Eric Eisenhauer, Irva E Veillard, Wataru Yamagami, Sarah J Hill, Kristopher A Sarosiek, Oladapo O Yeku, David R Spriggs, Bo R Rueda
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma. British journal of cancer 130 (9) (2024)
Eric J Rubin, Oladapo O Yeku, Stephen Morrissey
NEJM at ESMO - Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. The New England journal of medicine (2024)
Eric J Rubin, Oladapo O Yeku, Stephen Morrissey
NEJM at ESMO - Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. The New England journal of medicine (2024)
Yusuke Matoba, Dominique T Zarrella, Venkatesh Pooladanda, Maryam Azimi Mohammadabadi, Eugene Kim, Shaan Kumar, Mengyao Xu, Xingping Qin, Lauren J Ray, Kyle M Devins, Raj Kumar, Artem Kononenko, Eric Eisenhauer, Irva E Veillard, Wataru Yamagami, Sarah J Hill, Kristopher A Sarosiek, Oladapo O Yeku, David R Spriggs, Bo R Rueda
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma. British journal of cancer 130 (9) (2024)
Yusuke Matoba, Dominique T Zarrella, Venkatesh Pooladanda, Maryam Azimi Mohammadabadi, Eugene Kim, Shaan Kumar, Mengyao Xu, Xingping Qin, Lauren J Ray, Kyle M Devins, Raj Kumar, Artem Kononenko, Eric Eisenhauer, Irva E Veillard, Wataru Yamagami, Sarah J Hill, Kristopher A Sarosiek, Oladapo O Yeku, David R Spriggs, Bo R Rueda
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma. British journal of cancer 130 (9) (2024)
Eric J Rubin, Oladapo O Yeku, Stephen Morrissey
NEJM at ESMO - Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer. The New England journal of medicine (2024)
Ryan B Corcoran, Khanh T Do, Jeong Eun Kim, James M Cleary, Aparna Raj Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer T Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen X Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu, Geoffrey I Shapiro
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Yumin Wang, Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu, Haibo Yang, Fengqi Zhang, Xueping Zhu, Badi Zhou, Sean Yao, Aiko Nagayama, Sanghoon Lee, Jian Ouyang, Siang-Boon Koh, Eric L Eisenhauer, Dominique Zarrella, Kate Lu, Bo R Rueda, Lee Zou, Xiaofeng A Su, Oladapo O Yeku, Leif W Ellisen, Xiao-Song Wang, Li Lan
Author Correction: Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair. Nature communications 15 (1) (2024)
Yusuke Matoba, Dominique T Zarrella, Venkatesh Pooladanda, Maryam Azimi Mohammadabadi, Eugene Kim, Shaan Kumar, Mengyao Xu, Xingping Qin, Lauren J Ray, Kyle M Devins, Raj Kumar, Artem Kononenko, Eric Eisenhauer, Irva E Veillard, Wataru Yamagami, Sarah J Hill, Kristopher A Sarosiek, Oladapo O Yeku, David R Spriggs, Bo R Rueda
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma. British journal of cancer 130 (9) (2024)
Yumin Wang, Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu, Haibo Yang, Fengqi Zhang, Xueping Zhu, Badi Zhou, Sean Yao, Aiko Nagayama, Sanghoon Lee, Jian Ouyang, Siang-Boon Koh, Eric L Eisenhauer, Dominique Zarrella, Kate Lu, Bo R Rueda, Lee Zou, Xiaofeng A Su, Oladapo O Yeku, Leif W Ellisen, Xiao-Song Wang, Li Lan
Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair. Nature communications 15 (1) (2024)
Eric J Rubin, Oladapo O Yeku, Stephen Morrissey
NEJM at ESMO - Pembrolizumab in HER2+ Gastric Cancer. The New England journal of medicine (2024)
Ryan B Corcoran, Khanh T Do, Jeong Eun Kim, James M Cleary, Aparna Raj Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer T Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen X Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu, Geoffrey I Shapiro
Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Joyce F Liu, Stephanie Gaillard, Andrea E Wahner Hendrickson, Oladapo O Yeku, Elisabeth Diver, Camille Gunderson Jackson, Rebecca Arend, Elena Ratner, Vivek Samnotra, Divya Gupta, Jon Chung, Hailei Zhang, Natalie Compton, Amanda Baines, Emeline Bacqué, Xiaohong Liu, Brunella Felicetti, Gottfried E Konecny
Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO precision oncology 8 (2024)
Ryan B Corcoran, Khanh T Do, Jeong Eun Kim, James M Cleary, Aparna Raj Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer T Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen X Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu, Geoffrey I Shapiro
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Yumin Wang, Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu, Haibo Yang, Fengqi Zhang, Xueping Zhu, Badi Zhou, Sean Yao, Aiko Nagayama, Sanghoon Lee, Jian Ouyang, Siang-Boon Koh, Eric L Eisenhauer, Dominique Zarrella, Kate Lu, Bo R Rueda, Lee Zou, Xiaofeng A Su, Oladapo O Yeku, Leif W Ellisen, Xiao-Song Wang, Li Lan
Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair. Nature communications 15 (1) (2024)
Yusuke Matoba, Dominique T Zarrella, Venkatesh Pooladanda, Maryam Azimi Mohammadabadi, Eugene Kim, Shaan Kumar, Mengyao Xu, Xingping Qin, Lauren J Ray, Kyle M Devins, Raj Kumar, Artem Kononenko, Eric Eisenhauer, Irva E Veillard, Wataru Yamagami, Sarah J Hill, Kristopher A Sarosiek, Oladapo O Yeku, David R Spriggs, Bo R Rueda
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma. British journal of cancer (2024)
Ryan B Corcoran, Khanh T Do, Jeong Eun Kim, James M Cleary, Aparna Raj Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer T Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen X Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu, Geoffrey I Shapiro
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Ryan B Corcoran, Khanh T Do, Jeong Eun Kim, James M Cleary, Aparna Raj Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer T Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen X Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu, Geoffrey I Shapiro
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Yumin Wang, Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu, Haibo Yang, Fengqi Zhang, Xueping Zhu, Badi Zhou, Sean Yao, Aiko Nagayama, Sanghoon Lee, Jian Ouyang, Siang-Boon Koh, Eric L Eisenhauer, Dominique Zarrella, Kate Lu, Bo R Rueda, Lee Zou, Xiaofeng A Su, Oladapo O Yeku, Leif W Ellisen, Xiao-Song Wang, Li Lan
Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair. Nature communications 15 (1) (2024)
Eric J Rubin, Oladapo O Yeku, Stephen Morrissey
NEJM at ESMO - Preoperative Chemoradiotherapy for Resectable Gastric Cancer. The New England journal of medicine (2024)
Yumin Wang, Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu, Haibo Yang, Fengqi Zhang, Xueping Zhu, Badi Zhou, Sean Yao, Aiko Nagayama, Sanghoon Lee, Jian Ouyang, Siang-Boon Koh, Eric L Eisenhauer, Dominique Zarrella, Kate Lu, Bo R Rueda, Lee Zou, Xiaofeng A Su, Oladapo O Yeku, Leif W Ellisen, Xiao-Song Wang, Li Lan
Author Correction: Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair. Nature communications 15 (1) (2024)
Joyce F Liu, Stephanie Gaillard, Andrea E Wahner Hendrickson, Oladapo O Yeku, Elisabeth Diver, Camille Gunderson Jackson, Rebecca Arend, Elena Ratner, Vivek Samnotra, Divya Gupta, Jon Chung, Hailei Zhang, Natalie Compton, Amanda Baines, Emeline Bacqué, Xiaohong Liu, Brunella Felicetti, Gottfried E Konecny
Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO precision oncology 8 (2024)
Oladapo O Yeku, Dan L Longo
CAR T Cells for Neuroblastoma. The New England journal of medicine 388 (14) (2023)
Oladapo O Yeku
Racial disparities and referral for genetic counseling. Cancer (2023)
Oladapo O Yeku, Dan L Longo
Combination Therapy, Including Bevacizumab, for Advanced Colorectal Cancer. The New England journal of medicine 388 (18) (2023)
Linda R Duska, Dmitriy Zamarin, Erika Paige Hamilton, Amit M Oza, Gini F Fleming, Alexander I Spira, Oladapo O Yeku, Debra L Richardson, Jackie Walling, Kerry Inokuchi, Bernice Matusow, Gideon Bollag, Elizabeth M Swisher
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. JCO precision oncology 7 (2023)
Bradley J Monk, Christine Parkinson, Myong Cheol Lim, David M O'Malley, Ana Oaknin, Michelle K Wilson, Robert L Coleman, Domenica Lorusso, Paul Bessette, Sharad Ghamande, Athina Christopoulou, Diane Provencher, Emily Prendergast, Fuat Demirkiran, Olga Mikheeva, Oladapo O Yeku, Anita Chudecka-Glaz, Michael Schenker, Ramey D Littell, Tamar Safra, Hung-Hsueh Chou, Mark A Morgan, Vít Drochýtek, Joyce N Barlin, Toon Van Gorp, Frederick Rand Ueland, Gabriel Lindahl, Charles Anderson, Dearbhaile C Collins, Kathleen M Moore, Frederic Marmé, Shannon Neville Westin, Iain A McNeish, Danny Shih, Kevin K Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca S Kristeleit
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (34) (2022)
Panagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, Carolyn Krasner, Susana Campos, David L Kolin, Joyce F Liu, Neil Horowitz, Alexi A Wright, Sara Bouberhan, Richard T Penson, Oladapo O Yeku, Brittany Bowes, Hope Needham, Martin Hayes, Hannah Sawyer, Madeline Polak, Meghan Shea, Su-Chun Cheng, Cesar M Castro, Ursula A Matulonis
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Thapi D Rao, Mengyao Xu, Stephanie Eng, Guangli Yang, Robin Manson, Nestor Rosales, Raj Kumar, Irva E Veillard, Qin C Zhou, Alexia Iasonos, Ouathek Ouerfelli, David Shum, David R Spriggs, Oladapo O Yeku
Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents. Molecular cancer therapeutics 21 (5) (2022)
Amanda Ramos, Marcela Del Carmen, Oladapo O Yeku
PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature. Case reports in oncological medicine 2020 (2020)
Oladapo O Yeku, Andrea L Russo, Hang Lee, David Spriggs
A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma. Journal of translational medicine 18 (1) (2020)